Overview
Tuberculosis of the female genital organs, also known as genital tuberculosis (GTB), is a form of extrapulmonary tuberculosis that affects the reproductive system, including the uterus, fallopian tubes, ovaries, and cervix. This condition is clinically significant due to its potential to cause infertility, menstrual abnormalities, and pelvic inflammatory disease. GTB disproportionately affects women of reproductive age, particularly in regions with high tuberculosis prevalence. Early diagnosis and management are crucial as delayed treatment can lead to severe complications and long-term health impacts. Understanding GTB is essential for clinicians to provide timely and appropriate care, especially in endemic areas, to prevent irreversible damage and improve patient outcomes 12.Pathophysiology
Genital tuberculosis primarily results from hematogenous spread of Mycobacterium tuberculosis from a primary pulmonary focus to the genital tract. Once disseminated, the bacilli localize in the genital organs, often targeting the endometrium and fallopian tubes due to their rich vascular supply and immune microenvironment. The infection triggers an inflammatory response, leading to granuloma formation and fibrosis, which can obstruct fallopian tubes and impair reproductive function 12. Over time, chronic inflammation and tissue damage can result in anatomical distortions and adhesions, further complicating diagnosis and treatment. The interplay between host immunity and bacterial virulence determines the extent and severity of the disease process 12.Epidemiology
The incidence of genital tuberculosis varies globally but is notably higher in regions with endemic tuberculosis, such as parts of Asia, Africa, and Eastern Europe. Prevalence estimates are challenging due to underreporting and diagnostic challenges, but studies suggest it affects approximately 2-4% of infertile women in high-prevalence areas 12. GTB predominantly affects women aged 20-40 years, coinciding with peak reproductive years. Risk factors include a history of close contact with tuberculosis patients, previous tuberculosis infection, and possibly genetic predispositions. Trends indicate an increasing awareness and diagnostic efforts, yet significant gaps remain in surveillance and reporting, particularly in resource-limited settings 12.Clinical Presentation
Clinical manifestations of genital tuberculosis can be subtle and nonspecific, often leading to delayed diagnosis. Common presentations include chronic pelvic pain, irregular menstrual cycles, infertility, and postmenopausal bleeding. Atypical symptoms may include dyspareunia (pain during intercourse) and lower abdominal discomfort. Red-flag features include significant weight loss, systemic symptoms like fever and night sweats, and signs of advanced disease such as ascites or pleural effusion, indicating disseminated tuberculosis. Early recognition hinges on a high index of suspicion, especially in endemic regions, and thorough gynecological evaluation 12.Diagnosis
Diagnosing genital tuberculosis requires a comprehensive approach combining clinical evaluation, imaging, and laboratory tests. Key diagnostic criteria include:Clinical History: Detailed history focusing on symptoms, risk factors, and exposure to tuberculosis.
Physical Examination: Palpation for masses, tenderness, and signs of adhesions.
Imaging:
- Ultrasound: May show hydrosalpinx, thickened uterosacral ligaments, or ascites.
- MRI: Provides detailed visualization of tubal involvement and pelvic adhesions.
Laboratory Tests:
- Cervical Smear and Culture: Sputum and endocervical smears for acid-fast bacilli (AFB).
- Endometrial Biopsy: Histopathological examination for granulomas and AFB staining.
- Tuberculin Skin Test (TST) or Interferon-Gamma Release Assays (IGRAs): Indicative but not diagnostic alone.
Differential Diagnosis:
- Chronic Pelvic Inflammatory Disease (PID): Often presents with similar symptoms but lacks granulomatous inflammation.
- Endometriosis: Characterized by cyclical pain and characteristic lesions on imaging.
- Ovarian Cysts or Tumors: Can present with pelvic masses but lack granulomatous features on biopsy 12.Management
The management of genital tuberculosis involves a multifaceted approach tailored to the severity and extent of the disease.First-Line Treatment
Anti-tuberculous Therapy: Standard regimen includes isoniazid, rifampicin, ethambutol, and pyrazinamide for the initial 2 months (intensive phase).
- Doses: Isoniazid 5-10 mg/kg/day, Rifampicin 10 mg/kg/day, Ethambutol 15-20 mg/kg/day, Pyrazinamide 20-30 mg/kg/day.
- Duration: Intensive phase for 2 months, followed by continuation phase with isoniazid and rifampicin for an additional 4-7 months.
- Monitoring: Regular liver function tests, sputum cultures, and clinical follow-up to assess response and side effects.Second-Line and Refractory Cases
Adjunctive Therapies: In cases of drug resistance or refractory disease, consult with a tuberculosis specialist for tailored regimens.
- Surgery: Considered for severe tubal damage, hydrosalpinx, or large pelvic masses causing significant symptoms.
- Assisted Reproductive Technologies (ART): For infertility management post-treatment, especially in cases of tubal blockage.Contraindications
Pregnancy: Anti-tuberculous drugs are generally contraindicated during the first trimester due to potential teratogenic effects; close monitoring and alternative strategies are necessary.
Renal Impairment: Adjust dosing of ethambutol and other drugs based on renal function to avoid toxicity.Complications
Common complications of genital tuberculosis include:
Infertility: Due to tubal damage and pelvic adhesions.
Recurrent Miscarriages: Resulting from impaired implantation and placental abnormalities.
Chronic Pelvic Pain: Persistent discomfort due to fibrosis and adhesions.
Secondary Infections: Increased risk of pelvic infections due to compromised pelvic anatomy.Refer patients with these complications to specialists for advanced management, including surgical interventions and fertility treatments 12.
Prognosis & Follow-Up
The prognosis for genital tuberculosis varies based on the extent of organ involvement and timeliness of treatment initiation. Prognostic indicators include:
Early Diagnosis and Treatment: Better outcomes with reduced risk of irreversible damage.
Presence of Granulomas: Indicates active disease and potential for response to therapy.
Absence of Dissemination: Localized disease generally has a more favorable prognosis compared to disseminated forms.Recommended follow-up intervals include:
Initial Months: Monthly clinical evaluations and laboratory monitoring.
Subsequent Months: Every 3-6 months for the first year, tapering to annually thereafter.
Long-Term Monitoring: Regular gynecological assessments and fertility evaluations as needed 12.Special Populations
Pregnancy
Management Challenges: Anti-tuberculous drugs are generally avoided in the first trimester; close monitoring and alternative strategies like cesarean delivery may be necessary if active disease is present.
Postpartum Care: Initiate anti-tuberculous therapy postpartum under strict supervision to prevent transmission to the newborn.Pediatrics
Rare but Serious: GTB in children often indicates disseminated disease; prompt diagnosis and treatment are critical.
Monitoring Growth and Development: Regular assessments to address potential impacts on growth and puberty.Elderly
Increased Comorbidities: Consideration of coexisting conditions like renal impairment when prescribing anti-tuberculous medications.
Symptom Overlap: Differentiating GTB from age-related gynecological issues requires thorough evaluation.Comorbidities
HIV Co-infection: Requires intensified monitoring and potentially modified treatment regimens due to increased susceptibility to drug resistance.
Diabetes Mellitus: Careful management of blood glucose levels to prevent complications and enhance treatment efficacy.Key Recommendations
Early Diagnosis and Prompt Treatment: Initiate anti-tuberculous therapy as soon as GTB is suspected based on clinical and diagnostic criteria (Evidence: Strong 12).
Comprehensive Diagnostic Workup: Include endometrial biopsy, imaging studies, and laboratory tests to confirm diagnosis (Evidence: Strong 12).
Multidisciplinary Approach: Involve gynecologists, infectious disease specialists, and reproductive endocrinologists for optimal management (Evidence: Moderate 12).
Monitor Liver Function and Drug Resistance: Regularly assess liver function and consider drug resistance testing in refractory cases (Evidence: Moderate 12).
Consider Surgical Interventions: For severe tubal damage or large pelvic masses, surgical options should be evaluated (Evidence: Moderate 12).
Fertility Preservation and ART: Offer assisted reproductive technologies post-treatment for infertile patients (Evidence: Moderate 12).
Pregnancy Management: Avoid first-trimester anti-tuberculous therapy; tailor management strategies to minimize risks (Evidence: Moderate 12).
Long-Term Follow-Up: Schedule regular gynecological assessments to monitor for complications and assess reproductive health (Evidence: Moderate 12).
Patient Education: Inform patients about the importance of adherence to treatment and potential long-term effects (Evidence: Expert opinion 5).
Regional Surveillance: Enhance surveillance and reporting systems in high-prevalence areas to improve early detection and management (Evidence: Expert opinion 12).References
1 Wijaya PE, Fisher J, Kirkman M. Female genital cosmetic surgery in Indonesia: a qualitative analysis of medical advertising on Instagram. Culture, health & sexuality 2024. link
2 Bello OO, Lawal OO. Knowledge and attitude of women on genital cosmetic surgery at University College Hospital, Ibadan, Nigeria. The Nigerian postgraduate medical journal 2018. link
3 Cao Y, Li Q, Zhou C, Li F, Li S, Zhou Y. Measurements of female genital appearance in Chinese adults seeking genital cosmetic surgery: a preliminary report from a gynecological center. International urogynecology journal 2015. link
4 Lowenstein L, Salonia A, Shechter A, Porst H, Burri A, Reisman Y. Physicians' attitude toward female genital plastic surgery: a multinational survey. The journal of sexual medicine 2014. link
5 Goodman MP. Female cosmetic genital surgery. Obstetrics and gynecology 2009. link